Literature DB >> 20880730

Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity.

N Gupta1, I M Oppenheim, E F Kauvar, N Tayebi, E Sidransky.   

Abstract

Gaucher disease (GD), the most common lysosomal storage disease, results from a deficiency of the lysosomal enzyme glucocerebrosidase. GD has been classified into 3 types, of which type 2 (the acute neuronopathic form) is the most severe, presenting pre- or perinatally, or in the first few months of life. Traditionally, type 2 GD was considered to have the most uniform clinical phenotype when compared to other GD subtypes. However, case studies over time have demonstrated that type 2 GD, like types 1 and 3, manifests with a spectrum of phenotypes. This review includes case reports that illustrate the broad range of clinical presentations encountered in type 2 GD, as well as a discussion of associated manifestations, pathological findings, diagnostic techniques, and a review of current therapies. While type 2 GD is generally associated with severe mutations in the glucocerebrosidase gene, there is also significant genotypic heterogeneity. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20880730      PMCID: PMC3018671          DOI: 10.1016/j.bcmd.2010.08.012

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  108 in total

1.  Brainstem pathology of infantile Gaucher's disease with only wave I and II of auditory brainstem response.

Authors:  K Kaga; M Ono; K Yakumaru; M Owada; T Mizutani
Journal:  J Laryngol Otol       Date:  1998-11       Impact factor: 1.469

2.  Genotypic heterogeneity and phenotypic variation among patients with type 2 Gaucher's disease.

Authors:  N Tayebi; K J Reissner; E K Lau; B K Stubblefield; A C Klineburgess; B M Martin; E Sidransky
Journal:  Pediatr Res       Date:  1998-05       Impact factor: 3.756

3.  A novel complex allele and two new point mutations in type 2 (acute neuronopathic) Gaucher disease.

Authors:  G Sinclair; F Y Choy; L Humphries
Journal:  Blood Cells Mol Dis       Date:  1998-12       Impact factor: 3.039

Review 4.  Twenty five years of the "psychosine hypothesis": a personal perspective of its history and present status.

Authors:  K Suzuki
Journal:  Neurochem Res       Date:  1998-03       Impact factor: 3.996

5.  Is the perinatal lethal form of Gaucher disease more common than classic type 2 Gaucher disease?

Authors:  D L Stone; O P van Diggelen; J B de Klerk; J L Gaillard; M F Niermeijer; R Willemsen; N Tayebi; E Sidransky
Journal:  Eur J Hum Genet       Date:  1999 May-Jun       Impact factor: 4.246

Review 6.  Plasma and metabolic abnormalities in Gaucher's disease.

Authors:  J M Aerts; C E Hollak
Journal:  Baillieres Clin Haematol       Date:  1997-12

7.  Elevation of intracellular glucosylceramide levels results in an increase in endoplasmic reticulum density and in functional calcium stores in cultured neurons.

Authors:  E Korkotian; A Schwarz; D Pelled; G Schwarzmann; M Segal; A H Futerman
Journal:  J Biol Chem       Date:  1999-07-30       Impact factor: 5.157

8.  Technetium-99m-HmPAO brain SPECT in infantile Gaucher's disease.

Authors:  D S Lin; S P Lin; D C Liang; C S Ho; M C Wu
Journal:  Pediatr Neurol       Date:  1999-01       Impact factor: 3.372

9.  The human chitotriosidase gene. Nature of inherited enzyme deficiency.

Authors:  R G Boot; G H Renkema; M Verhoek; A Strijland; J Bliek; T M de Meulemeester; M M Mannens; J M Aerts
Journal:  J Biol Chem       Date:  1998-10-02       Impact factor: 5.157

10.  Type 2 Gaucher disease with hydrops fetalis in an Ashkenazi Jewish family resulting from a novel recombinant allele and a rare splice junction mutation in the glucocerebrosidase locus.

Authors:  K Reissner; N Tayebi; B K Stubblefield; V Koprivica; M Blitzer; W Holleran; T Cowan; S Almashanu; A Maddalena; E M Karson; E Sidransky
Journal:  Mol Genet Metab       Date:  1998-04       Impact factor: 4.797

View more
  29 in total

Review 1.  Revised recommendations for the management of Gaucher disease in children.

Authors:  Paige Kaplan; Hagit Baris; Linda De Meirleir; Maja Di Rocco; Amal El-Beshlawy; Martina Huemer; Ana Maria Martins; Ioana Nascu; Marianne Rohrbach; Lynne Steinbach; Ian J Cohen
Journal:  Eur J Pediatr       Date:  2012-07-08       Impact factor: 3.183

2.  Gaucher disease type 2: homozygosity for the mutation F331S in two unrelated consanguineous Muslim Arab patients with Gaucher disease from the Gaza and Jenin regions.

Authors:  Hagit N Baris; Annick Raas-Rothschild; Ben-Zion Garty; Ruth Tor; Sarah Klontz; Nahid Tayebi; Ellen Sidransky; Ian J Cohen
Journal:  Blood Cells Mol Dis       Date:  2011-09-01       Impact factor: 3.039

Review 3.  The clinical management of Type 2 Gaucher disease.

Authors:  Karin Weiss; Ashley Gonzalez; Grisel Lopez; Leah Pedoeim; Catherine Groden; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2014-11-14       Impact factor: 4.797

4.  Skin ultrastructural findings in type 2 Gaucher disease: diagnostic implications.

Authors:  Aegean Chan; Walter M Holleran; Tajh Ferguson; Debra Crumrine; Ozlem Goker-Alpan; Raphael Schiffmann; Nahid Tayebi; Edward I Ginns; Peter M Elias; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2011-09-16       Impact factor: 4.797

Review 5.  Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history.

Authors:  Hagit N Baris; Ian J Cohen; Pramod K Mistry
Journal:  Pediatr Endocrinol Rev       Date:  2014-09

6.  Gaucher Disease - A Rare Cause of Collodion.

Authors:  Zhi Xuen Low; Gopakumar Hariharan
Journal:  Indian J Pediatr       Date:  2019-09-16       Impact factor: 1.967

7.  Neuronopathic Gaucher disease: dysregulated mRNAs and miRNAs in brain pathogenesis and effects of pharmacologic chaperone treatment in a mouse model.

Authors:  Nupur Dasgupta; You-Hai Xu; Ronghua Li; Yanyan Peng; Manoj K Pandey; Stuart L Tinch; Benjamin Liou; Venette Inskeep; Wujuan Zhang; Kenneth D R Setchell; Mehdi Keddache; Gregory A Grabowski; Ying Sun
Journal:  Hum Mol Genet       Date:  2015-09-29       Impact factor: 6.150

8.  Recent advances in the diagnosis and management of Gaucher disease.

Authors:  Sam E Gary; Emory Ryan; Alta M Steward; Ellen Sidransky
Journal:  Expert Rev Endocrinol Metab       Date:  2018-03-12

Review 9.  Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease.

Authors:  Olive Jung; Samarjit Patnaik; Juan Marugan; Ellen Sidransky; Wendy Westbroek
Journal:  Expert Rev Proteomics       Date:  2016-04-21       Impact factor: 3.940

10.  Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration.

Authors:  Tamar Farfel-Becker; Einat B Vitner; Samuel L Kelly; Jessica R Bame; Jingjing Duan; Vera Shinder; Alfred H Merrill; Kostantin Dobrenis; Anthony H Futerman
Journal:  Hum Mol Genet       Date:  2013-09-24       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.